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Abstract
Background: Muscular dystrophies are a clinically and genetically heterogeneous group of disorders characterized
by variable degrees of progressive muscle degeneration and weakness. There is a wide variability in the age of
onset, symptoms and rate of progression in subtypes of these disorders. Herein, we present the results of our study
conducted to identify the pathogenic genetic variation involved in our patient affected by rigid spine muscular
dystrophy.
Case presentation: A 14-year-old boy, product of a first-cousin marriage, was enrolled in our study with failure to
thrive, fatigue, muscular dystrophy, generalized muscular atrophy, kyphoscoliosis, and flexion contracture of the
knees and elbows. Whole-exome sequencing (WES) was carried out on the DNA of the patient to investigate all
coding regions and uncovered a novel, homozygous missense mutation in SEPN1 gene (c. 1379 C > T, p.Ser460Phe).
This mutation has not been reported before in different public variant databases and also our database
(BayanGene), so it is classified as a variation of unknown significance (VUS). Subsequently, it was confirmed that the
novel variation was homozygous in our patient and heterozygous in his parents. Different bioinformatics tools
showed the damaging effects of the variant on protein. Multiple sequence alignment using BLASTP on ExPASy and
WebLogo, revealed the conservation of the mutated residue.
Conclusion: We reported a novel homozygous mutation in SEPN1 gene that expands our understanding of rigid
spine muscular dystrophy. Although bioinformatics analyses of results were in favor of the pathogenicity of the
mutation, functional studies are needed to establish the pathogenicity of the variant.
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Background
Muscular dystrophies are a group of disorders with het-
erogeneous clinical, genetic, and biochemical presenta-
tion. They are usually recognized by variable degrees of
progressive muscle degeneration and weakness affecting
limb, axial, and facial muscles. In some types of these
disorders, muscles of the respiratory system and heart,
as well as the swallowing process can be involved.
Rarely, other tissues and organs, including brain, inner
ear, eyes, or skin are also affected. There is a wide vari-
ability in the age of onset, symptoms and rate of pro-
gression in different forms of these disorders [1–3].
During the past decade, muscular dystrophies have ex-
tensively been studied. These advancements have been
largely due to the breakthroughs developed in molecular
genetics techniques, which have paved the way for the
identification of the genetic and molecular basis of many
of these disorders, improvements in the standards of care,
and novel treatment approaches. Currently, performing
molecular genetic diagnosis is very useful for establish-
ment of phenotype-genotype correlations, pre-marital
genetic counseling, prenatal diagnosis, and disease prog-
nosis as well as identification of new treatments for these
disorders [4–9].
Since identification of the exact function of genes in-
volved in muscular dystrophies, as well as the patho-
logical mechanisms and phenotypic consequences of
mutations may shed light on therapeutic strategies for
these disorders, the objective of our study was to find
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the genetic cause of muscular dystrophy in our patient
and report the associated observed clinical presentations.
Case presentation
A 14-year-old boy (height = 140 cm, weight = 18 kg) from
Fars province, southern Iran, who was born to
first-cousin parents without family history of any genetic
disorders, was referred to our center with failure to
thrive, fatigue, muscular dystrophy, generalized muscular
atrophy, kyphoscoliosis, and flexion contracture of the
knees and elbows (Fig. 1). His motor symptoms started
at the age of four years with frequent episodes of falling
down that had progressed in subsequent years. There
were no other family members with similar signs or
symptoms. He walked at the age of 11 months and had
no motor milestone delay. He had two previous admis-
sions to the pediatric intensive care unit due to pneumo-
nia and respiratory distress. The patient had nasal
speech and sleep apnea and was under treatment with
BiPAP breathing machine. By the age of 12, he was
noted to have scoliosis requiring bracing.
On physical examination, the patient was cachectic
with generalized muscular atrophy. Decreased muscle
power in the shoulder-girdle muscles, foot extensors and
limb muscles (4/5 MRC muscle scale) was noted. He
also had pes cavus and contracture of both knees and el-
bows. He was also found to have severe spine rigidity
with a chin-sternum distance of 15 cm.
Transthoracic echocardiography was only notable for
mild pulmonary hypertension and mild tricuspid regur-
gitation. Pulmonary function testing revealed a FEV1 of
35% and FVC of 32% of the predicted values.
Serum calcium and phosphorus levels were 8.2 and
3.1 mg/dL, respectively. The patient had abnormally high
levels of creatine phosphokinase (CPK) (340 U/L) and
lactate dehydrogenase (LDH) (1200 U/L).
Nerve conduction study was normal. However, needle
electromyography (EMG) examination revealed myo-
pathic changes in deltoid, biceps, tibialis anterior, and
rectus femoris muscles, in favor of Emery-Dreifuss mus-
cular dystrophy.
To identify the mutated gene involved, whole-exome
sequencing (WES) was used on genomic DNA extracted
from EDTA blood of the patient. Next generation se-
quencing (NGS) was carried out on an Illumina NextSeq
500 platform to investigate all coding regions and their
boundaries. WES details of coverage and number of
reads are provided in Table 1. NGS data were analyzed
using different bioinformatics tools and databases [10].
NGS data identified a novel, homozygous missense mu-
tation in SEPN1 gene (chr1:25812784, NM_020451.2:
exon:10, c. 1379 C > T, p.Ser460Phe). This mutation has
not been reported before in different public variant data-
bases and also our database (BayanGene), so it is classi-
fied as a variation of unknown significance (VUS). To
confirm the novel mutation identified in our patient,
Sanger sequencing was performed using primers cover-




Sanger sequencing confirmed the identified mutation in
SEPN1 in proband as homozygous (T/T). His mother, father
and brother were confirmed to be heterozygous (C/T), and
his sister homozygous for the wildtype allele (C/C) (Fig. 2).
In order to predict the conservation of the mutated resi-
due, we used different bioinformatics tools, including the
Basic Local Alignment Search Tool (BLAST BLASTP ver
2.2.31+) on ExPASy (available from: https://web.expa-
sy.org/cgi-bin/blast/BLAST.pl) and WebLogo (https://
weblogo.berkeley.edu/logo.cgi).
Bioinformatics analysis predicted that this mutation is
damaging and can affect the proper function of the pro-
tein (Table 2). In addition, multiple protein sequence
alignment revealed conservation of the most residues of
SEPN1 across different species (Fig. 3a and b). Serine resi-
due is conserved among studied species (Fig. 3a). The fre-
quency of serine in this position is more than that for
glycine and proline—only these two amino acids replace
serine in other species. Since phenylalanine residue is not
among these frequent amino acids, the replacement of
serine with phenylalanine is predicted to be deleterious.
Discussion and conclusion
Desmin-related myopathies (DRM) are a group of mus-
cular disorders with heterogeneous clinical presentation
Fig. 1 Generalized muscular atrophy, kyphoscoliosis, and flexion
contracture of the knees and elbows in our patient
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and genetic basis, characterized by intrasarcoplasmic des-
min aggregation. It has been found that around 30% of
DRM are resulted from impaired desmin gene. The impair-
ment in the structure and subsequent accumulation of des-
min result in spinal rigidity, limitation of neck and trunk
flexion, progressive scoliosis, early notable limited flexion of
the lumbar and cervical spine, which ultimately lead to loss
of the spine and thoracic cage movements [11].
Rigid spine muscular dystrophy-1 and myopathy, con-
genital, with fiber-type disproportion (CFTD) result from
disease-causing mutations in SEPN1 gene (606210), lo-
cated on chromosome 1p36, which encodes selenoprotein
N, a glycoprotein found within the endoplasmic reticulum
(ER) [12].
Selenoproteins, which contain selenocysteine residue,
are vital for a wide range of biological pathways [13, 14].
Table 1 Whole Exome Sequencing detail of coverage and number of reads
Type Value Type Value
Total Reads 11,709,761 Percent reads on target 95.70%
Passed filter Unique Reads aligned 11,648,030 Percent Passed filter Unique Reads aligned 99.77%
Mean Target Coverage 85X Percent on Target 92.01%
Percent Duplicate 10.94% Duplicate in analysis 0%
Capture Method Agilent Inherited Disease Total Genes Covered 3204
Run method NextSeq 500 Sequence length 151 Pair-End
Phred Quality Score above 38 90% GC content 55%
Nucleotide Covered GTE_1 100% Nucleotide Covered GTE_5 99%
Nucleotide Covered GTE_8 98% Nucleotide Covered GTE_10 97%
Nucleotide Covered GTE_15 91% Nucleotide Covered GTE_20 83%
Nucleotide Covered GTE_30 69% Nucleotide Covered GTE_40 56%
Nucleotide Covered GTE_50 44% Nucleotide Covered GTE_60 35%
Nucleotide Covered GTE_70 27% Nucleotide Covered GTE_80 21%
Nucleotide Covered GTE_90 16% Nucleotide Covered GTE_100 13%
GTE Greater or equal to #
Fig. 2 Pedigree and Sanger sequencing chromatogram of family involved in this study
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Table 2 Results of bioinformatics analyses of the novel mutation in this study
Chr Start Ref Alt Function Gene BayanGene avsnp147 Frequency
1 25,812,784 C T exonic SELENON 1 rs767530943 0.000018
SIFT Polyphen2 LRT Mutation Taster Mutation Assessor FATHMM REVEL MCAP CADD _phred
D D N D M D 0.73 . 18.91
Fig. 3 a: Graphical representation of amino acid multiple sequence alignment among different species. It shows degree of conservation for
amino acids 447–465 of SEPN1 protein. Position 460 (serine) indicates the mutated residue in our study. It has middle conservation degree (2 bits)
and also shows that it is replaced by two other amino acids, i.e., glycine and proline in other species but not by phenylalanine. A logo represents
the height of each letter proportional to the observed frequency of the corresponding amino acid. The overall height of each stack is
proportional to the sequence conservation, measured in bits, at that position. The maximum sequence conservation per site is log2 20 ≈ 4.32 bits
for proteins. The protein sequence alignment was performed for the following species: Homo sapiens (Q9NZV5), Gorilla gorilla gorilla (G3R759),
Pongo abelii (H2N8I1), Papio anubis (A0A2I3MR13), Rhinopithecus roxellan (A0A2K6RVS9), Sus scrofa (A1E950), Bos taurus (F1MD36), Myotis lucifugus
(G1P3X6), Dipodomys ordii (A0A1S3GIF9), Equus caballus (F7BM99), Loxodonta africana (G5E785), and Mus musculus (D3Z2R5). b: Multiple protein
sequence alignment of SEPN1 across different kingdoms
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Twenty-five selenoprotein-encoding genes have been
identified in human genome [15]. The SEPN1 contains a
single selenocysteine residue and has an ER-addressing
and -retention signal, indicating its localization within
the ER [16, 17]. High level of expression of SEPN1 has
been found in several human fetal tissues, including
muscles. However, the level of expression is lower in
adult tissues, indicating its key role during early stages
of embryogenesis, in early development and in cell pro-
liferation [17, 18]. SEPN1 has a Ca2+-binding domain that
is involved in the biochemical processes regulating the re-
lease of intracellular calcium. This protein is essentially in-
volved in oxidation and reduction reactions, mainly on
calcium pumps, modifying the regulation of calcium in ER
[19]. Calcium homeostasis is crucial for normal develop-
ment and differentiation of muscle. Therefore, SEPN1 pro-
tein is a vital component in the process of muscle fiber
formation and fiber specification [20].
In fact, supporting evidence suggests that selenium,
among all its biological roles, is also influential on the nor-
mal physiologic state of striated muscles. For instance, sel-
enium deficiency leads to acquired cardiomyopathy [21]
and white muscle disease [22]. Likewise, the SEPN1 muta-
tions are associated with muscular dystrophies.
So far, four autosomal-recessive neuromuscular disor-
ders, collectively regarded as SEPN1-related myopathies
(SEPN-RM), have been identified [23]. Those include
rigid spine muscular dystrophy (RSMD1) [24, 25], the
classical form of multiminicore disease (MmD) [23],
desmin-related myopathy with Mallory-body like inclu-
sions (MB-DRM) [26], and CFTD [27]. Patients with
SEPN-RM present with similar clinical findings, mainly
early-onset hypotonia and muscular atrophy, particularly
in axial musculature, along with ensuing scoliosis, neck
weakness, and spinal rigidity. In patients with impaired
respiratory ventilation, fatal prognosis is also expected
[28]. However, the disease onset, clinical course and out-
come of patients can be very variable [29].
The first SEPN1 mutation related to a human genetic
disorder was found in 2001 in patients affected by con-
genital RSMD [24]. Over the recent years, various patho-
genic and non-pathogenic variations have been
identified across SEPN1 [30, 31]. The initial approach
for a reliable clinical diagnosis of these disorders is doing
a magnetic resonance imaging (MRI) of muscles, and
measuring the growth hormone level, metabolic and
muscular serum markers, and performing electrodiag-
nostic studies and echocardiography [32–38].
In conclusion, we identified a novel SENP1 mutation,
which is predicted to be deleterious due to high damaging
scores extracted from various bioinformatics software,
conservation of amino acid in studied position, confirm-
ation of mutation in the family, and absence of the muta-
tion in our databases (1000 Iranian Genome).
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